The Drug Enforcement Administration (DEA) has scheduled a hearing to consider differing expert opinions on the Justice Department’s proposal to federally reschedule marijuana—an extra procedural step that will take place after the November election. After moving to reclassify cannabis as a Schedule III drug under the Controlled Substances Act (CSA) back in March, DOJ opened […]
Shocking how easily they can escalate a scheduled drug but ask the FDA to de-schedule and all of a sudden they become nothing but red tape and bureaucracy.
Shocking how easily they can escalate a scheduled drug but ask the FDA to de-schedule and all of a sudden they become nothing but red tape and bureaucracy.